Neurobiology of Opioid Dependence: 2 - 2 - Full Text View

Neurobiology of Opioid Dependence: 2 - 2

This study has been completed.

Sponsors and Collaborators:	National Institute on Drug Abuse (NIDA) Yale University
Information provided by:	National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:	NCT00000193

Purpose

The purpose of this study is to evaluate the effects of gamma hydroxybutyric on naloxone-precipitated opiate withdrawal.

Condition	Intervention	Phase
Opioid-Related Disorders	Drug: Gamma hydroxybutyric	Phase II

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Double-Blind, Placebo Control

Official Title:	Neurobiology of Opioid Dependence: 2

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:

Estimated Enrollment:	0
Study Start Date:	January 1996

Eligibility

Genders Eligible for Study:	Male
Accepts Healthy Volunteers:	No

Criteria

Please contact site for information.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000193

Locations


United States, Connecticut
	VA Connecticut Healthcare System
	New Haven, Connecticut, United States, 06519

Sponsors and Collaborators

National Institute on Drug Abuse (NIDA)

Yale University

Investigators


Principal Investigator:	Marc I Rosen, M.D.	VA Connecticut Healthcare System

More Information

Study ID Numbers:	NIDA-00191-2, K20-00191-2
First Received:	September 20, 1999
Last Updated:	June 23, 2005
ClinicalTrials.gov Identifier:	NCT00000193
Health Authority:	United States: Federal Government

Study placed in the following topic categories:

Mental Disorders

Substance-Related Disorders

Disorders of Environmental Origin

Opioid-Related Disorders

ClinicalTrials.gov processed this record on October 31, 2008